Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of October 2018. The registrant is a foreign private issuer based in Jerusalem, Israel, focused on developing the product candidate M-001.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The primary financial event reported is the receipt of debt financing:
- Debt Financing: Received the third and final tranche of a loan from the European Investment Bank (EIB).
- Tranche Amount: €8 million.
- Total Loan Received: €20 million (cumulative).
- Loan Purpose: Financing up to 50% of the expected costs for developing and marketing M-001.
Material Changes
The material change reported is the completion of the €20 million finance contract with the EIB. Previous tranches were received in June 2018 and August 2018, with this October 2018 disbursement finalizing the agreement.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future performance, or a detailed risk factor section beyond the context of the financing agreement. The document serves primarily to disclose the completion of the loan disbursement.
Investor Verification Checklist
- Verify the total cumulative loan amount received from the EIB is €20 million.
- Confirm the loan terms and repayment schedule associated with the EIB finance contract.
- Review the attached press release (Exhibit 99.1) for details on the utilization of funds for M-001.
- Note that this filing does not contain updated revenue or profitability metrics.